OA-SYS
/ Ageless Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
March 03, 2025
OA-SYS-01: An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint
(clinicaltrials.gov)
- P2 | N=400 | Recruiting | Sponsor: Ageless Biotech, Inc. | Trial completion date: May 2028 ➔ Dec 2028 | Initiation date: Jan 2025 ➔ Apr 2025
Trial completion date • Trial initiation date • Immunology • Osteoarthritis • Pain • Rheumatology
January 29, 2025
OA-SYS-01: An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
(clinicaltrials.gov)
- P2 | N=400 | Recruiting | Sponsor: Ageless Biotech, Inc. | Initiation date: Oct 2024 ➔ Jan 2025
Trial initiation date • Immunology • Osteoarthritis • Pain • Rheumatology
August 12, 2024
OA-SYS-01: A Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
(clinicaltrials.gov)
- P2 | N=400 | Recruiting | Sponsor: Ageless Biotech, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Osteoarthritis • Pain • Rheumatology
July 03, 2024
OA-SYS-01: A Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
(clinicaltrials.gov)
- P2 | N=400 | Not yet recruiting | Sponsor: Ageless Biomed, Inc
New P2 trial • Immunology • Osteoarthritis • Pain • Rheumatology
April 19, 2022
Ageless Biotech Engages Board of Director for United States MMA Federation as Principal Investigator for FDA Investigational New Drug (IND) Phase II Trial
(PRNewswire)
- "Ageless Biotech...is proud to have Board Certified Orthopedic Surgeon Dr. Randa Bascharon as a Principal Investigator for Ageless Biotech's U.S. Food and Drug Administration (FDA) Investigational New Drug Application (IND) for the treatment of Osteoarthritis of the Knee."
IND • CNS Disorders • Osteoarthritis • Pain
1 to 5
Of
5
Go to page
1